Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cetin, 2010, Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program, Urology, 75, 1396, 10.1016/j.urology.2009.07.1360
Gandaglia, 2014, Distribution of metastatic sites in patients with prostate cancer: a population-based analysis, Prostate, 74, 210, 10.1002/pros.22742
Pond, 2014, The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer, Eur Urol, 65, 3, 10.1016/j.eururo.2013.09.024
Vinjamoori, 2012, Atypical metastases from prostate cancer: 10-year experience at a single institution, AJR Am J Roentgenol, 199, 367, 10.2214/AJR.11.7533
Halabi, 2003, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer, J Clin Oncol, 21, 1232, 10.1200/JCO.2003.06.100
Omlin, 2013, Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms, Eur Urol, 64, 300, 10.1016/j.eururo.2012.12.029
Armstrong, 2007, A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis, Clin Canc Res, 13, 6396, 10.1158/1078-0432.CCR-07-1036
Pezaro, 2014, Visceral disease in castration-resistant prostate cancer, Eur Urol, 65, 270, 10.1016/j.eururo.2013.10.055
Ost, 2014, Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer, Prostate, 74, 297, 10.1002/pros.22750
Halabi, 2014, Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer, J Clin Oncol, 32, 671, 10.1200/JCO.2013.52.3696
Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012
Klabunde, 2000, Development of a comorbidity index using physician claims data, J Clin Epidemiol, 53, 1258, 10.1016/S0895-4356(00)00256-0
Lu-Yao, 2012, Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?, Eur Urol, 62, 966, 10.1016/j.eururo.2012.05.003
Gandaglia, 2014, Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer, Eur Urol, 66, 1125, 10.1016/j.eururo.2014.01.026
Furuya, 1998, Prognosis of patients with prostate carcinoma presenting as nonregional lymph node metastases, Urol Intern, 61, 17, 10.1159/000030277
Pound, 1999, Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 281, 1591, 10.1001/jama.281.17.1591
Chornokur, 2011, Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer, Prostate, 71, 985, 10.1002/pros.21314
Mariotto, 2007, Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey, Cancer, 109, 1877, 10.1002/cncr.22607
Schroder, 2012, Prostate-cancer mortality at 11 years of follow-up, N Engl J Med, 366, 981, 10.1056/NEJMoa1113135
Tsingotjidou, 2001, Development of an animal model for prostate cancer cell metastasis to adult human bone, Anticanc Res, 21, 971
Jacob, 1999, Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone, Cancer Res, 59, 4453
O’Kelly, 2014, Characteristics of modern Gleason 9/10 prostate adenocarcinoma: a single tertiary centre experience within the Republic of Ireland, World J Urol, 32, 1067, 10.1007/s00345-013-1184-2
Sathiakumar, 2011, Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006, Prostate Cancer Prostatic Dis, 14, 177, 10.1038/pcan.2011.7
Briganti, 2014, Treatment of lymph node-positive prostate cancer: teaching old dogmas new tricks, Eur Urol, 65, 26, 10.1016/j.eururo.2013.07.003
Heesakkers, 2008, MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study, Lancet Oncol, 9, 850, 10.1016/S1470-2045(08)70203-1
Barekati, 2012, Methylation signature of lymph node metastases in breast cancer patients, BMC Cancer, 12, 244, 10.1186/1471-2407-12-244
Arya, 2006, The metastatic cascade in prostate cancer, Surg Oncol, 15, 117, 10.1016/j.suronc.2006.10.002
Halabi, 2010, The importance of identifying and validating prognostic factors in oncology, Semin Oncol, 37, e9, 10.1053/j.seminoncol.2010.04.001
Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096
Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755
De Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618
Frohmuller, 1995, Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone, Eur Urol, 27, 202, 10.1159/000475161
Suardi, 2015, Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years, Eur Urol, 67, 299, 10.1016/j.eururo.2014.02.011
Onukwugha, 2012, Bone metastasis (BM) based on SEER registry versus Medicare claims among metastatic prostate cancer (PCa) patients (pts) in SEER-Medicare [abstract e15148], J Clin Oncol, 30